Activated Carbon For Pharma & Healthcare Market Size, Share & Trends Analysis Report By Form (Powdered, Granular), By Application (API Production, Finished Drug Production), By Region, And Segment Forecasts

Market Size & Trends

The size of the global activated carbon for pharma & healthcare market was approximated at USD 450.1 million in the year 2024 and will grow at a CAGR of 6.3% between 2025 and 2035.

Its superior purification as well as adsorption capabilities drive the increasing growth of activated carbon in the health care and pharma industries. It has a significant application in uses like air and water decontamination in hospitals and drug production, where it purifies medications by removing impurities and colouring matter.

Increased demand for activated carbon in the health industry is directly related to the high prevalence of hospital-acquired infections (HAIs) in the United States. Annually, approximately 1.7 million inpatients-about one in 20-develop an HAI, with 5% to 10% of hospitalized patients being affected and almost 100,000 resulting fatalities. These striking statistics outweigh the occurrence and fatality rates of a great many other reportable illnesses, making critical the need for state-of-the-art air and water cleansing technologies Activated carbon, widely recognized for its great filtration as well as adsorption property, is rapidly being embraced to assist in the upkeep of sterile conditions and limiting the risk of infection within medical centers.

Additionally, demand is fueled by its critical function in decolorization and purification. Its very porous nature, strengthened through thermal activation, facilitates effective impurities, pigments, and dyes adsorption. This enhances product quality, safety, and appearance. Activated carbon is used extensively during manufacturing to capture undesirable substances, producing cleaner, more efficient drugs. The growing R&D spend by the industry further drives demand for high-performance purification products like activated carbon. These trends drive demand for activated carbon for the pharma & healthcare industry.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand

• Competitive benchmarking
• Historical data & forecasts
• Company revenue shares
• Regional opportunities
• Latest trends & dynamics

Form Insights

Powdered form led the activated carbon in the pharma & healthcare segment with the highest revenue share of 56.3% in 2024. Powdered Activated Carbon (PAC) has been found effective in minimizing pharmaceutical compounds in wastewater, with 63-84% removal of discharged carbamazepine and diclofenac at dosing concentrations of 10-25 mg/L. PAC is a critical tool to manage pharmaceutical pollutants in municipal wastewater treatment. It also improves sludge quality, raising the dry weight by +1% while restricting the increase in sludge production to 7-9%, leading to better waste management

The granular activated carbon market is anticipated to expand at the highest CAGR of 6.9% during the forecast period. The granular type is favored by greater numbers of pharma and healthcare firms due to its primary characteristics, including better absorption, ease of storage and handling, and ability to regenerate. The repetitive cycle withstanding capability of granular activated carbon is largely responsible for the increased adoption. Greater cooperation and supply agreements between industry participants also contribute to this growth experience of the segment. In 2024, Arq, Inc., one of the leading producers of Granular Activated Carbon (GAC), reported that it won several supply contracts for its GAC product, primarily intended for processes involved in raw material purification.

Application Insights

The API manufacturing dominated the activated carbon for pharma & healthcare market with the highest revenue share in 2024. While producing APIs, i.e., the essential part of drugs, accounting for their medicinal activity, activated carbon assists in the removal of impurities, decolorization, pH correction, stability, avoiding contamination, and improving product quality. The pharmaceutical sector is among the fastest-developing industries globally, with active pharmaceutical ingredients being in the center of this evolution.

The completed drug manufacturing segment is anticipated to increase substantially during the forecast period. Activated carbon is a critical component in the treatment of pharmaceutical wastewater, eliminating leftover drugs and impurities to maintain environmental standards following drug manufacturing.

Regional Insights

The activated carbon for pharma & healthcare market in Asia Pacific dominated the global market with the largest revenue share of 48.6% in 2024. The demand is rising due to rapid industrialization and urbanization. Increased pharmaceutical production in Asian countries further drives the need for efficient purification. Leading companies such as Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., and Cipla contribute significantly to this demand, using activated carbon in various drug manufacturing and filtration processes.

Global Activated Carbon for Pharma & Healthcare Market – Regional Market Size

Assumptions

• Base Year 2024 (USD 450.1 million)

• Forecast CAGR (2025–2035) 6.3%

• Estimated Regional Share Split (industry-aligned)

  • Asia Pacific 38%

  • North America 28%

  • Europe 22%

  • Latin America 7%

  • Middle East & Africa 5%

• 2035 Total Market Value
  $450.1 \times (1.063)^{11} = \approx 850.9$ million USD

Regional Market Size Table (2024–2035)

China Activated Carbon For Pharma & Healthcare Market Trends

The China activated carbon for pharma & healthcare market led the Asia Pacific market with the highest revenue share in 2024. The growing pharmaceutical and healthcare industries in China drive the demand for activated carbon used to purify APIs and intermediates in pharmaceutical production. Since 2021, the market has expanded at a rate of 9.3% annually, driven by the 14th Five-Year Plan, the Ministry of Industry and Information Technology said. Harsh environmental protections on pharmaceutical pollution and waste disposal have boosted demand for activated carbon to purify air and water. Furthermore, activated carbon tablets and capsules are sold extensively in hospitals and pharmacies to cure poisoning, indigestion, and flatulence.

North America Activated Carbon For Pharma & Healthcare Market Trends

The pharma & healthcare activated carbon market in North America accounted for a high market share in 2024. The expansion of pharmaceutical production industries and developments in cleaner healthcare industries are fueling market demand. In addition, it is also employed to cure over-the-counter stomach problems, which are increasing steadily as per the American Gastroenterological Association (AGA). In 2022, 60-70 million Americans were reported to be afflicted with gastrointestinal diseases. Furthermore, North America alone had 49.1% of the world's pharmaceutical sales  in 2021, demonstrating the region's leading status in the global pharma market, driving the need for activated carbon.

The U.S. activated carbon for pharma & healthcare market emerged as the leading market in North America, capturing the highest revenue share in 2024. The rising demand is being fueled by a number of underlying factors, including mounting regulatory pressures by bodies like the FDA, coupled with tighter environmental regulations, that are compelling businesses to implement higher levels of purity and filtration standards in drug production. Activated carbon fulfills these requirements by purifying active pharmaceutical ingredients and intermediates of impurities. Its use in medicine, especially in the treatment of drug overdoses, has become more critical, as exemplified by the 105,007 overdose fatalities in 2023 . Increased environmental and health consciousness also promotes cleaner and more sustainable production processes in the healthcare industry.

Europe Activated Carbon For Pharma & Healthcare Market Trends

Activated carbon for pharma & healthcare in Europe had a high market share in 2024. Demand is primarily increasing due to its growing application across different industries, such as pharma. The pharmaceutical industry invested more than USD 53.5 million in R&D  in Europe in 2022. In addition, the rising digestive disorder in Europe is also a key driver for activated carbon, as it is used to control some of its symptoms. In 2023, more than 332 million individuals are estimated to be suffering from a digestive disorder in the region, according to a report by United European Gastroenterology (UEG). 

Key Activated Carbon For Pharma & Healthcare Company Insights

Some key players in the activated carbon for pharma & healthcare market are Osaka Gas Chemicals Co., Ltd., Calgon Carbon Corporation, JACOBI CARBONS GROUP, and Cabot Corporation. These organizations emphasize developing new purification technologies, adhering to stringent regulatory requirements, and growing product applications. They emphasize high-quality, efficient solutions for drug manufacturing, wastewater treatment, and medical applications such as poisoning therapies. Robust R&D expenditures and collaborative partnerships with major pharma firms also support growth.

Osaka Gas Chemicals Co., Ltd. manufactures products like activated carbon, carbon fiber, fine chemicals, and wood preservatives. The firm caters to different industries, including pharmaceuticals, electronics, and environmental industries, and it is committed to innovation and sustainability in its products and operations.

Calgon Carbon Corporation produces wood, coconut, and coal-derived activated carbon products in powdered, granular, pelletized, and cloth types.

Key Activated Carbon For Pharma & Healthcare Companies

The following are the leading companies in the activated carbon for pharma & healthcare market. These companies collectively hold the largest market share and dictate industry trends.

• Jacobi Group
• Chemviron (a Kuraray Company)
• Haycarb PLC
• Boyce Carbon
• Southern Carbon Pvt. Ltd.
• Suneeta Carbons
• Calgon Carbon Corporation
• Karbonous Inc.
• Norit
• Donau Carbon GmbH

Recent Developments

• In February 2025, JACOBI CARBONS GROUP announced that a 15-20% price increase would be implemented from April 2025 on all coconut shell-based activated carbons. A recent surge in raw material costs necessitated the adjustment.

• In December 2024, CPL/Puragen Activated Carbons, ADBA members, won the Energy Innovation award at the MRW National Recycling Awards 2024 for their breakthrough in reactivating high-sulfur spent carbon from the biogas sector-a previously untreatable waste.

Activated Carbon For Pharma & Healthcare Market Report Scope

Report Attribute	Details
Market size value in 2025	USD 479.7 million
Revenue forecast in 2030	USD 652.1 million
Growth rate	CAGR of 6.3% from 2025 to 2035
Base year for estimation	2024
Historical data	2018 - 2023
Forecast period	2025 - 2035
Quantitative units	Volume in kilotons, revenue in USD million, and CAGR from 2025 to 2035
Report coverage	Volume & revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Form, application, region
Regional scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope	U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; South Africa; Saudi Arabia
Key companies profiled	Jacobi Group; Chemviron (a Kuraray Company); Haycarb PLC; Boyce Carbon; Southern Carbon Pvt. Ltd.; Suneeta Carbons; Calgon Carbon Corporation; Karbonous Inc.; Norit; Donau Carbon GmbH
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Activated Carbon For Pharma & Healthcare Market Report Segmentation

Form Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2035)

• • Powdered       

  • Granular

  • Other Form

• Application Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2035)

  • API Production

  • Finished Drug Production

  • Others

• Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2035)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia